Introduction: Little is known regarding efficacy and effectiveness of electroconvulsive therapy (ECT) discharge (p=0.001), 6th month (p=0.053) and at 12th month (p=0.003).
INTRODUCTION
Over the past decade, schizophrenia has become more treatable than before, due to increased use of new generation of drug therapies. Progressive neuro-scientific advances will hold out strong possibilities of more definite biological treatments in near future. Despite this, historical importance of electroconvulsive therapy (ECT) continues in patients with schizophrenia. Though most reviewers conclude that the presence of depression is a factor predicting a positive effect of ECT in schizophrenia 1 , many studies contradict these findings. Erwin & Thompson 2 believed that ECT does not treat the schizophrenic process but rather treats secondary mood disorders in schizophrenia. Wells 3 examined records in a university hospital over 10 years and found that 76 percent of schizophrenia patients given ECT for the first time had moderate to severe depression and 54 percent had depression as the most prominent symptom. Patients with schizoaffective disorder and catatonia had the best response rate (85% and 82%, respectively). Despite these facts, ECT has been found to be very efficacious in schizophrenia, especially in first-break psychotic patients with excitement, over activity, florid delusion and severe hallucination which might create difficulties in initial management of patients. If patient is treated at the earliest course of illness especially who are young, the risk of chronicity, personality deterioration can be avoided and patient can be put in remission quite early 4 .
Most of the previous studies had focused on efficacy of ECT acute schizophrenia with catatonic Original Article subtype. 5, 6, 7, 8 ECT has also been used in chronic schizophrenia-also described as "last resort" in various literatures and in some cases treatment resistant schizophrenia (TRS). 9, 10, 11, 12, 13, 14, 15 But we all know 30-50% of patients of schizophrenia have difficulties in initial psychotropic treatment 16 , with 10-15% developing treatment resistant even in the first episode. 17, 18 Considering long term debilitating condition of schizophrenia, it is important to intervene at the earliest stage of disease process since we have effective physical treatment in the form of ECT for nearly 70 years.
There are very few studies in the treatment of first episode schizophrenia (FES) by ECT with or without medications. But these studies are only cross-sectional with retrospective data analysis. Though Nepal has been using ECT for the last 40 years, no scientific research has been done so far. This will be the first study of its' kind that has been done in Nepal. In this study, outcome and efficacy of ECT was assessed in patients with first episode schizophrenia (FES).
MATERIAL AND METHODS:
Study Design-This was a naturalistic prospective study of patients who were admitted in the inpatient unit of medical college psychiatry department. Patients were assessed by qualified psychiatrists and diagnosis of schizophrenia was done as per ICD-10. 19 Inclusion criteria: Patients and informants who were willing to participate in the study and gave consent. History had certain evidence that it was first episode schizophrenia (FES). Patients who had history of excitement /over activity / self-harm & harm to others and extremely difficult to manage in wards despite adequate psychotropic drugs. Final decision to give ECT was decided by psychiatrists.
Exclusion criteria: Patients and informants who refused to give consent. Any evidences of past history of psychotic spectrum disorders and history of bipolar disorders. History of alcohol and substance abuse. Other general medical conditions that led to psychotic symptoms. No previous antipsychotic treatment and inpatient care.
Apart from informed consent from patients and relatives, ethical guidelines for biomedical research on human subjects by Nepal Health Research Council (NHRC) were also adhered to, in addition to principles enunciated in the "declaration of Helsinki". Ethical approval from the "Institute Ethical Committee" of the medical college was also taken. Sample consists of 45 patients with diagnosis of FES. Of them, 12 patients were given ECT (considered as ECT-receivers or ECT-R) and 33 patients did not receive ECT (considered as ECTnon-receivers or ECT-NR). They were assessed at the time of admission, at discharge, during first month / sixth month and at twelfth month of follow-up. 20 . Patient's day to day functional status was assessed by administering Global Assessment of Function (GAF) 21 ECT Technique: Pre-anesthetic assessment was necessary a day prior to procedure from the anesthesia department.
Assessment
ECT was done under general anesthesia using anesthetic agents such as Propofol (2-5mg/kg) or Sodium Thiopentone (10-15mg/kg). Succinylcholine (20-30mg/kg) was used as a muscle relaxant after above mentioned agents. Masked ventilation was also done using 100% oxygen and vital signs were monitored along with ECG throughout the procedure. One of the arms was spared with B.P. cuff before administrating muscle relaxant so that adequate convulsing can be seen during ECT. At least 15 seconds of convulsion was considered as an effective convulsion though it varies from 10 seconds to 120 seconds depending upon the dose of anesthetic agents and clamping of BP cuff. Upward titration of electrical dose was done according to clinical improvement of the patients. Patients were shifted to post-operative ward after they become conscious, they were kept there for at least 2 hours and shifted to psychiatric ward.
ECT machine: The machine used for administering ECT was ECTON constant current and brief pulse ECT which has been manufactured by RMS, Chandigarh, India. This machine has of two types of operations -Brief Pulse Mode 1(PLS1); Brief Pulse Mode 2 (PLS2); The Sine Wave. Almost all of the procedure used in this study was done using PLS-1 to maintain uniformity in the procedure. Concurrent medications: All patients were continued on the same antipsychotic drugs at the same dose when they underwent ECT. Non-antipsychotic drugs were limited to trihexyphenidyl for extra pyramidal symptoms, benzodiazepines for sleep / anxiety and other medications for nonspecific symptoms like body ache, headache. No other psychotropics other than mentioned above were used and no antidepressants were used. None of the patients in the study were on any long term medications for chronic medical illnesses. Patients who were not given ECT were also continued on the same medications as before and non-psychotic drugs were also limited as on ECT users.
Statistical Analysis: Statistical analysis was performed with SPSS program (version 12). Data interpretation was done along with mean, standard deviation. Tests for the statistical significance of the associations between the variables were also done.
RESULT:
There were 12 patients who received ECT (as ECT receivers / ECT-R) compared with 33 patients who did not received ECT (as non-receivers / ECT-NR).These two groups of patients were compared in socio-demographic profile (age, gender, educational level, marital status and occupation) as shown in table 1. Table 2 showed duration of hospitalization (DUH) and duration of illness (DUI). The mean DUH in ECT-receivers (ECT-R) was 25.42 days in ECT-nonreceivers (ECT-NR) was 34.75 days, there was decrement of nearly 9 days in ECT-R. The mean DUI was 206.88 days in ECT-R whereas it was 297.08 days in ECT-NR. Though it was first episode schizophrenia (FES) DUI in ECT-R was shorter as compare to ECT-NR, patients were given ECT due to reasons described above. Table 3 showed psychopathological assessment using Brief Psychiatric Research Scale (BPRS) done at admission, discharge, 1 st month, 6 th month and at 12 th month in patients between non-receivers and receivers. As compared to ECT non-receivers, there were significant improvement in BPRS in ECT receivers at that time of discharge (ECT-R=39.33; ECT-NR=48.21; TOTAL=45.84; p=0.001), 1 st month (ECT-R=31.5; ECT-NR=38.76; TOTAL= 36.82; p= 0.001), 6 th month (ECT-R=26.08; ECT-NR=32.42; TOTAL=30.73; p=0.001) and at 1 st year (ECT-R=22.58; ECT-NR=26.48; TOTAL=25.44). Measurement decrements were more than 40-50% from the time of admission which as compared to ECT non-receivers were statistically significant.
Patient's day to day functional status was measured by Global Assessment of Function (GAF) ( Table 4) at admission, discharge and at 6 th month and at 12 th month. As compared to non-receivers, ECT receivers had significant improvement in GAF at discharge (ECT-R=61.08; ECT-NR=53.33; TOTAL=54.67; p=0.001), at 6 th month (ECT-R=73.75; ECT-NR=67.42; TOTAL=69.11; TOTAL=0.053) and at 1 st year (ECT-R=87.08; ECT-R=79.64; TOTAL=81.62; p=0.003). GAF measurement was improved by more than 50% in ECT receivers which were statistically significant. Measurement improvement was more than 40-50% from the time of admission which as compared to ECT nonreceivers were statistically significant. We believe this study is the first of its kind done in Nepal where ECT is infamously known in Nepal as "Bijuli ko Jhadka" or "Electric Shock" and carries misconception not only among lay people but also among medical professionals and media, which further contributes to negative stigmatization 22 . This leads to great resistance from patients and their family members. Thus ECT in Nepal is an important effective treatment but most of the time underutilized and often ignored. All first episode schizophrenia (FES) patients who received ECT in this study showed significant improvement in psychopathology and day to day functioning. Their quality of life improved, with great reduction in requirement of psychotropic drugs. The one year follow-up was achievable in all the patients who underwent ECT. Patients were in follow-up further than our study period of 12 months. This study is unique in a way that ECT was used FES as various literature considers ECT only in affective psychopathology. In acutely violent and agitated patients or patients showing disorganized and excited behavior, it would be extremely difficult and problematic to keep patients only on psychotropic drugs for 6-8 weeks as recommended by guidelines. Side effects of drugs and longer duration of hospitalizations also has to be considered. These are the reasons why ECT was considered in FES in this study. As shown in other studies in FES 23, 24 . Most of the patients in this study had diagnosis of catatonic, paranoid, and undifferentiated schizophrenia (table5). Though it is well known from study that ECT is effective in catatonic subtype 25, 26, 27, 28 , this study also showed effectiveness of ECT in paranoid and disorganized subtype. There are few limitations of this study: (1) it is an open label study. (2) Psychotropic drugs and their doses were altered according to clinical judgment. (3) As ECT is not considered first line treatment in FES in most of the treatment protocol, this study had restricted indications for ECT leading to less number of ECT receivers than non-receivers. This will have difficulties in generalizing our findings in patients with FES. Historically, ECT has been poorly studied because of various reasons, like stigma and prejudice attached to the treatment, including technical drawbacks in the designs of the studies or general ambivalence in the medical and research community towards its use 29 . Though there is negative attitude in the community regarding its use, our study showed ECT to be highly efficacious treatment even in severe mental illness, like FES.
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CONCLUSION:
Though used infrequently, ECT in young first episode schizophrenia give significant overall improvement and wellbeing with very minimal side-effects. ECT also shortens duration of hospitalization with early discharge and improvement in psychosocial wellbeing.
